Rare Tumors (Jul 2013)

Radiotherapy for metastatic fibrolamellar hepatocellular carcinoma

  • Justin G. Peacock,
  • Jason A. Call,
  • Kenneth R. Olivier

DOI
https://doi.org/10.4081/rt.2013.e28
Journal volume & issue
Vol. 5, no. 3
pp. e28 – e28

Abstract

Read online

Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare variant of hepatocellular carcinoma (HCC) that commonly affects young individuals without a prior history of liver disease. FLHCC commonly results in a better prognosis than HCC; however, the risk of recurrence and metastatic disease is high. FLHCC is typically treated by primary resection of the tumor with 50-75% cure rates. The use of radiation therapy in FLHCC has not been assessed on its own, and may show some success in a very few reported combination therapy cases. We report on the successful use of radiation therapy in a case of metastatic FLHCC to the lung following primary and secondary resections. Our treatment of the large, metastatic, pulmonary FLHCC tumor with 40 Gy in 10 fractions resulted in an 85.9% tumor volume decrease over six months. This suggests FLHCC may be a radiosensitive tumor and radiotherapy may be valuable in unresectable or metastatic tumors.

Keywords